Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,472.00
Bid: 12,492.00
Ask: 12,496.00
Change: 74.00 (0.60%)
Spread: 4.00 (0.032%)
Open: 12,432.00
High: 12,526.00
Low: 12,318.00
Prev. Close: 12,398.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Hutchmed notes phase 2 trial; Tricorn drops 25%

Wed, 28th Jul 2021 10:58

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Hutchmed (China) Ltd, up 9.0% at 585.08 pence, 12-month range 337.00p-656.00p. Alongside AstraZeneca PLC, the Hong Kong-based pharmaceutical company kicks off a phase 2 trial of Orpathys in some cancer patients. A first patient was dosed on Tuesday. The trial will probe the effectiveness of Orpathys in sufferers of advanced or metastatic MET amplified gastric cancer, - cancer formed in the lining of the stomach - or adenocarcinoma of the gastroesophageal junction, cancer of the oesophagus which connects a body's mouth to the stomach. Metastatic cancer refers to when the disease spreads to other parts of the body.

----------

Staffline PLC, up 9.1% at 63.50p, 12-month range 23.24p-82.38p. The recruitment and training firm rises in a positive read-across from mid-cap peer FDM Group Holdings PLC. FDM's pretax profit for the six months to June 30 falls 3.3% to GBP20.5 million from GBP21.2 million. The London-based firm posted revenue of GBP131.3 million, down 6.5% from GBP140.5 million. However, recruitment and training levels ramped up significantly in the first half to meet growing client demand, FDM says. Its stock was 3.0%.

----------

Empire Metals Ltd, up 7.8% at 2.59 p, 12-month range 1.70p-5.73p. The resource exploration and development company says the third phase of reverse circulation drilling of Eclipse gold project in Australia shows "encouraging results". Drilling confirms the existence of "additional mineralised zones".

----------

AIM - LOSERS

----------

Tricorn Group PLC, down 25% at 3.77p, 12-month range 3.16p-9.00p. The Worcestershire-based tube parts manufacturer hits this 12-month low on Wednesday as it warns that, while it is working within its lending facilities, it may soon need to operate outside of them as cost pressures ramp up. Tricorn notes global supply chain disruption as well as pressure on operating costs, margins and working capital. What's more, some overdue debts from customers are still outstanding. "Whilst the group's principal lending bank is expected to remain supportive, certain restrictions on these facilities are being imposed," Tricorn cautions, adding that these curbs will be eased in the event of an injection of funds.

----------

Total Produce PLC, down 16% at 177.92p, 12-month range 85.75p-235.00p. The fresh produce firm says the initial public offering price for joint venture company Dole PLC has been cut to between USD16 and USD17 per share from USD20 to USD23 previously. Total Produce says its shareholders will own just over 57% of Dole post-IPO, down from just shy of 62%.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
20 Jun 2024 10:56

TOP NEWS: AstraZeneca's Truqap gets OK from EU for breast cancer form

(Alliance News) - AstraZeneca PLC on Thursday said that the EU approved its prescription medicine Truqap, in combination with hormonal therapy Faslodex, for the treatment of a form of breast cancer.

Read more
18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

Read more
18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with inflation data and central bank decisions the key plot points as the week progresses.

Read more
18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with paclitaxel did not achieve its primary endpoints.

Read more
17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "important new option" for patients.

Read more
17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Bank of England.

Read more
17 Jun 2024 07:23

IN BRIEF: AstraZeneca gets positive cancer test results for Calquence

AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.

Read more
17 Jun 2024 07:15

AstraZeneca's Imfinzi gets US approval for endometrial cancer patients

(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.

Read more
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.